Marc is a senior CMC consultant with a broad and varied experience, covering projects from preclinical to commercial, from small molecules to biologics and ATMP, in various dosage forms. He mostly supports startup biotech companies as Head of CMC, developing strategies, identifying and engaging with external partners and CDMOs, executing projects to ensure drug supply and regulatory approval.

Marc is attending BOS Basel 2025 in his role as Director Process Development at Disruptive Pharma, an innovative clinical stage biotech and drug delivery company leveraging its innovative mesoporous magnesium carbonate (MMC) technology to enable amorphous drug formulations.

Presentation Title: Streamlined and Cost-Efficient Drug Product Development from Lab to Market with Mesoporous Magnesium Carbonate (MMC) ​

Abstract: Key Differentiators of MMC Technology – Unlocking the Full Potential of Small Molecule Drugs

- Superior Bioavailability & Stability – Enhances solubility with proven long-term stability (>52 months), MMC dissolves in the GIT providing complete dissolution and optimized for poorly soluble drugs.

- Highly Processable Amorphous Powder with Excellent Flowability – Ideal for tableting and capsule filling

- High Drug Loading of Final Product – Enables fewer and smaller tablets/capsules with less additional excipients.

- Optimized for Cost-Efficient & Scalable Manufacturing – Over 95% yield, sustainable process with low solvent use versus traditional ASD technologies.

- Accelerated Time to Market – MMC is applicable in all development/clinical stages, streamlining progress to commercialization.

View company profile